EMANATE, a global Phase 3 study of setmelanotide across four heterozygous MC4R-pathway genetic subgroups, missed its primary endpoint of...

Preclinical data point to restored GNE protein expression and increased sialic acid production following intravenous delivery of a dual-function...

At Week 104 of the pivotal ApproaCH trial in children with achondroplasia, once-weekly TransCon CNP (navepegritide) maintained gains in...

Propanc Biopharma has signed a services agreement with Berlin-based FyoniBio to develop and validate an LC-MS pharmacokinetics assay capable...

Aptorum Group and DiamiR Biosciences reported peer‑reviewed evidence that plasma microRNA signatures can detect glioblastoma, publishing feasibility findings in...

Polyrizon has completed GMP manufacturing of clinical trial material for its lead intranasal hydrogel after two prior development batches...

InnoCare has dosed the first healthy volunteer in China with ICP-538, an oral VAV1-directed molecular glue degrader. It is...

Greenwich LifeSciences announced mid-trial use of commercially manufactured GP2 in its Phase III FLAMINGO-01 study. What looks like a...

In earlier clinical work, the alpibectir–ethionamide combination (AlpE) delivered a 7‑day early bactericidal activity signal comparable to isoniazid and...

BridgeBio’s BBP-418 delivered functional and biomarker gains in the Phase 3 FORTIFY interim analysis for LGMD2I/R9: at 12 months,...